Clearmind Medicine says US publishes MDMA-PEA patent application for PTSD treatment
CMND•US publication of patent application
Clearmind Medicine says the U.S. has published its patent application covering a combination of MDMA and N-acylethanolamines for treating post-traumatic stress disorder (PTSD).
Broader therapeutic claims and collaboration
The application also targets anxiety and eating disorders, with palmitoylethanolamide cited as a lead N-acylethanolamine in the claimed methods.
Clearmind said its collaboration with NeuroThera integrates its PEA technology, and the partners now cite 13 joint patent applications filed globally.
Potential treatment economics and FDA guidance
Clearmind said the approach could improve MDMA treatment economics through lower dosing, fewer side effects and a wider therapeutic window.
The disclosure follows FDA final guidance dated July 13, 2026, outlining clinical development considerations for psychedelic drugs, including MDMA.
